. 2019 Jun 5;39(8):957–966. doi: 10.1177/0333102419855080

Table 5.

Summary of TEAEs that occurred in 2% or more of patients in any lasmiditan dose group and more frequently with lasmiditan than placebo (p < 0.05).

	Placebo (n = 1262)	Lasmiditan 50 mg (n = 654)	Lasmiditan 100 mg (n = 1265)	Lasmiditan 200 mg (n = 1258)	Lasmiditan pooled doses (n = 3177)
Dizziness	37 (2.9)	56 (8.6)^a	194 (15.3)^a,b	216 (17.2)^a,b	466 (14.7)^a
OR vs. placebo		3.7	6.0	6.9	5.7
Paresthesia	19 (1.5)	16 (2.4)^a	73 (5.8)^a,b	91 (7.2)^a,b	180 (5.7)^a
OR vs. placebo		2.7	4.0	5.1	4.1
Somnolence	27 (2.1)	35 (5.4)^a	65 (5.1)^a	75 (6.0)^a	175 (5.5)^a
OR vs. placebo		2.7	2.5	2.9	2.7
Fatigue	8 (0.6)	18 (2.8)^a	52 (4.1)^a	50 (4.0)^a	120 (3.8)^a
OR vs. placebo		3.0	6.7	6.5	6.0
Nausea	20 (1.6)	18 (2.8)	52 (4.1)^a	50 (4.0)^a	107 (3.4)^a
OR vs. placebo		2.3 (ns)	2.0	2.5	2.3
Muscular weakness	0	7 (1.1)^a	16 (1.3)^a	19 (1.5)^a	42 (1.3)^a
OR vs. placebo		na	na	na	na
Hypoesthesia	3 (0.2)	2 (0.3)	17 (1.3)^a,b	20 (1.6)^a	39 (1.2)^a
OR vs. placebo		1.0 (ns)	5.7	6.8	5.3

Number of patients (%) reported. OR: odds ratio point estimate; vs: versus; na: not applicable.

Significant difference vs. placebo (p < 0.05).

Significant difference vs. lasmiditan 50 mg (p < 0.05).

No significant differences between lasmiditan 100 mg vs. 200 mg.